Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Author:
Publisher
Frontiers Media SA
Subject
Immunology,Immunology and Allergy
Reference188 articles.
1. Ovarian cancer statistics, 2018;Torre;CA Cancer J Clin,2018
2. Therapeutic applications of PARP inhibitors in ovarian cancer;Xie;Biomed Pharmacother,2020
3. PARP inhibitors in ovarian cancer;Franzese;Cancer Treat Rev,2019
4. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response;Francica;Genome Med,2018
Cited by 191 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ganoderic acid T, a Ganoderma triterpenoid, modulates the tumor microenvironment and enhances the chemotherapy and immunotherapy efficacy through downregulating galectin-1 levels;Toxicology and Applied Pharmacology;2024-10
2. TCEB2/HIF1A signaling axis promotes chemoresistance in ovarian cancer cells by enhancing glycolysis and angiogenesis;European Journal of Medical Research;2024-09-11
3. Identification of RTP4 facilitating ovarian cancer by bioinformatics analysis and experimental validation;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-09-09
4. Mitochondrial activity related genes of mast cells identify poor prognosis and metastasis of ovarian cancer;Immunobiology;2024-09
5. Methotrexate-modified docetaxel liposome targeting with ginsenoside Rh2 as a membrane stabilizer for the treatment of ovarian cancer;Journal of Drug Delivery Science and Technology;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3